Life Sciences
Gross to Net
GTN Modeling is a Differentiator for Life Sciences Companies
Life Sciences and Pharmaceutical manufacturers can use a consistent process across business functions and centralized, real-time data in a connected Anaplan model to more accurately forecast utilization and discounting by market segment, starting at the contract level.
By integrating gross-to-net management, manufacturers can quantitatively assess the amount of discounts flowing through each contract component and market segment, ultimately improving their ability to predict net revenue in future periods. This further enables improved accuracy of accruals and better-informed reserves, with potentially immediate impact on the bottom line.
Net Revenue Forecasting Challenges
Life Sciences & Pharmaceutical manufacturers find it difficult to forecast their net revenue because product pricing adjustments (discounts) to their gross revenue are highly complex, vary greatly across market segments and customers, and contain high-data volumes to process.
This difficulty in ability to forecast net sales directly impacts accrual management and product reserve accuracy. Moreover, due to the complexity and uniqueness of pricing adjustments, traditional spreadsheet-based approaches to forecasting lack scalability and are unable to incorporate interdependencies between market segments.
Real-life collaboration
Version management
Flexibility and configurability
High-data volumes across multiple market segments
Native audit trail
Forecast accuracy
A streamlined and centralized system
No disruption to upstream/downstream activities
Solution Benefits
